Make 45,000 vials of rBCG available for the United States
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Mar 2025
- Due
- 31 Dec 2025
- Delivered
- by 13 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ImmunityBio anticipates that over 45,000 vials of rBCG will be available for the United States in 2025 to address the overall BCG shortage.”
What we found
Evidence strength A What the grades mean
ImmunityBio made over 45,000 vials of rBCG available for the U.S. in 2025 via FDA-authorized expanded access, with shipments beginning in Q1 2025.
-
A Press Release dated March 3, 2025
“ImmunityBio anticipates that over 45,000 vials of rBCG will be available for the United States in 2025 to address the overall BCG shortage.” ✓ confirmed on the page
-
A ImmunityBio 10-K Filing - Year Ended December 31, 2025
“In Q1 2025, shipments commenced under the EAP.” ✓ confirmed on the page
-
B ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S.
“U.S. Urology Partners, one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG)” ✓ confirmed on the page
-
D Anktiva shortage: What providers and prescribers need to know in 2026
“The company's recombinant BCG (rBCG) program has dosed over 570 patients through expanded access at 58 sites”
Checked 8 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Make
- Deliverable
- 45,000 vials of rBCG
- Target
- 45,000 vials
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-IBRX-002823 · Corrections policy